Dawn Langdon shares her insights on significant recent developments including the Brief International Cognitive Assessment for MS (BICAMS), a fast, easy-to-administer and already widely validated neuropsychological battery for cognition in MS, as well as an important new study on Benefit and Risk information for Medication in MS (BRIMMS).
1. What are the most significant recent developments in your area? (0:05)
2. Can you tell us about the presentations you have been involved in here? (0:38)
3. What challenges do you face when treating patients with MS? (2:41)
Speaker disclosures: Dawn Langdon is a speaker bureau participant for Bayer, Merck, Almirall, Excemed, TEVA, Roche, Novartis, Biogen and Sanofi; consultant to Novartis, Bayer, Merck, Biogen, Teva and Sanofi; receives research grants from Bayer, Merck, Novartis and Biogen. All are paid to Royal Holloway, University of London.
Filmed at the 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, France, October 2017.
Share this Video
Related Videos In Multiple Sclerosis
Lawrence Steinman, EAN 2021: Hot Topics in Multiple Sclerosis
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA) to discuss some of the hot topics and research trends in the field of multiple sclerosis for 2021/22. Question: What are the hot topics and latest research […]
Lawrence Steinman EAN, 2021: Results from the Phase 3 ULTIMATE I and II Trials
It was a pleasure to meet with Lawrence Steinman (Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA, USA), to discuss the results from the Phase 3 ULTIMATE I and II trials, investigating ublituximab versus teriflunomide in relapsing multiple sclerosis. The abstract entitled: ‘Ublituximab versus teriflunomide […]
Patrick Vermersch, EAN 2021: Tolebrutinib in Patients with Progressive Multiple Sclerosis: Phase 3 PERSEUS and HERCULES Trials
It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis. The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!